Polyclonal Antibodies Against Equine Rhinitis A Virus 3AB, 3C and 3D Proteins
Technology description
Equine rhinitis A virus, formerly known as equine rhinovirus 1, causes a respiratory disease in horses similar to the common cold in humans. No vaccines against this virus are available commercially and no specific antiviral treatment exists. UW-Madison researchers have developed polyclonal antibodies against recombinant proteins from equine rhinitis A virus.The antibodies can be used for specific molecular recognition of the equine rhinitis A virus proteins in vitro or in vivo using experimental techniques such as ELISA (enzyme linked immunosorbent assay), Western assays, protein immunoprecipitation (IP) and confocal fluorescence microscopy.
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in polyclonal antibodies against several equine rhinitis A virus proteins.
Application area
- Studying equine rhinitis A virus proteins
- May lead to new means of detecting, preventing and treating equine rhinitis A virus infection
Advantages
- All reagents have been tested for efficacy.
- Most of the antibodies react with viral precursor proteins, in addition to the mature proteins against which they were raised.
March 14, 2017
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium